Template:Table of severe drug reactions - Revision history

Rossdonaldson1: /* Table of Severe Drug Rashes */

2019-12-17T19:25:03Z

Table of Severe Drug Rashes

← Older revision		Revision as of 19:25, 17 December 2019
Line 6:		Line 6:
	\| align="center" style="background:#f0f0f0;"\|'''[[AGEP]]'''		\| align="center" style="background:#f0f0f0;"\|'''[[AGEP]]'''
	\| align="center" style="background:#f0f0f0;"\|'''[[Erythroderma]]'''		\| align="center" style="background:#f0f0f0;"\|'''[[Erythroderma]]'''
			\|-
			\| '''Image'''\|\|[[File:PMC3894017 JFMPC-2-83-g001.png\|250px]] \|\|[[File:Stevens-johnson-syndrome.jpg\|150px]] \|\| [[File:Acute generalized exanthematous pustulosis.png\|200px]] \|\|[[File:Red (burning) Skin Syndrome - Feet Collage.jpg\|250px]]
	\|-		\|-
	\| '''Onset of eruption'''\|\|2-6 weeks\|\|1-3 weeks\|\|48 hours\|\|1-3 weeks		\| '''Onset of eruption'''\|\|2-6 weeks\|\|1-3 weeks\|\|48 hours\|\|1-3 weeks
Line 32:		Line 34:
	\|-		\|-
	\| '''Mortality''' (%)\|\|10\|\|5-35\|\|5\|\|5-15		\| '''Mortality''' (%)\|\|10\|\|5-35\|\|5\|\|5-15
	\|-
	\| '''Image'''\|\|[[File:PMC3894017 JFMPC-2-83-g001.png\|250px]] \|\|[[File:Stevens-johnson-syndrome.jpg\|150px]] \|\| [[File:Acute generalized exanthematous pustulosis.png\|200px]] \|\|[[File:Red (burning) Skin Syndrome - Feet Collage.jpg\|250px]]
	\|}		\|}

Rossdonaldson1: /* Table of Severe Drug Rashes */

2019-12-17T19:24:31Z

Table of Severe Drug Rashes

← Older revision		Revision as of 19:24, 17 December 2019
Line 33:		Line 33:
	\| '''Mortality''' (%)\|\|10\|\|5-35\|\|5\|\|5-15		\| '''Mortality''' (%)\|\|10\|\|5-35\|\|5\|\|5-15
	\|-		\|-
	\| '''Image'''\|\|[[File:PMC3894017 JFMPC-2-83-g001.png\|250px]] \|\|[[File:Stevens-johnson-syndrome.jpg\|150px]] \|\| \|\|[[File:Red (burning) Skin Syndrome - Feet Collage.jpg\|250px]]		\| '''Image'''\|\|[[File:PMC3894017 JFMPC-2-83-g001.png\|250px]] \|\|[[File:Stevens-johnson-syndrome.jpg\|150px]] \|\| [[File:Acute generalized exanthematous pustulosis.png\|200px]] \|\|[[File:Red (burning) Skin Syndrome - Feet Collage.jpg\|250px]]
	\|}		\|}

Rossdonaldson1: /* Table of Severe Drug Rashes */

2019-12-17T19:23:34Z

Table of Severe Drug Rashes

← Older revision		Revision as of 19:23, 17 December 2019
Line 33:		Line 33:
	\| '''Mortality''' (%)\|\|10\|\|5-35\|\|5\|\|5-15		\| '''Mortality''' (%)\|\|10\|\|5-35\|\|5\|\|5-15
	\|-		\|-
	\| '''Image'''\|\|[[File:PMC3894017 JFMPC-2-83-g001.png\|250px]] \|\|[[File:Stevens-johnson-syndrome.jpg\|~~250px~~]] \|\| \|\|[[File:Red (burning) Skin Syndrome - Feet Collage.jpg\|250px]]		\| '''Image'''\|\|[[File:PMC3894017 JFMPC-2-83-g001.png\|250px]] \|\|[[File:Stevens-johnson-syndrome.jpg\|150px]] \|\| \|\|[[File:Red (burning) Skin Syndrome - Feet Collage.jpg\|250px]]
	\|}		\|}

Rossdonaldson1: /* Table of Severe Drug Rashes */

2019-12-17T19:23:13Z

Table of Severe Drug Rashes

← Older revision		Revision as of 19:23, 17 December 2019
Line 33:		Line 33:
	\| '''Mortality''' (%)\|\|10\|\|5-35\|\|5\|\|5-15		\| '''Mortality''' (%)\|\|10\|\|5-35\|\|5\|\|5-15
	\|-		\|-
	\| '''Image'''\|\|[[File:PMC3894017 JFMPC-2-83-g001.png\|250px]] \|\| \|\| \|\|[[File:Red (burning) Skin Syndrome - Feet Collage.jpg\|250px]]		\| '''Image'''\|\|[[File:PMC3894017 JFMPC-2-83-g001.png\|250px]] \|\|[[File:Stevens-johnson-syndrome.jpg\|250px]] \|\| \|\|[[File:Red (burning) Skin Syndrome - Feet Collage.jpg\|250px]]
	\|}		\|}

Rossdonaldson1: /* Table of Severe Drug Rashes */

2019-12-17T19:22:25Z

Table of Severe Drug Rashes

← Older revision		Revision as of 19:22, 17 December 2019
Line 33:		Line 33:
	\| '''Mortality''' (%)\|\|10\|\|5-35\|\|5\|\|5-15		\| '''Mortality''' (%)\|\|10\|\|5-35\|\|5\|\|5-15
	\|-		\|-
	\| '''Image'''\|\| \|\| \|\| \|\|[[File:Red (burning) Skin Syndrome - Feet Collage.jpg\|250px]]		\| '''Image'''\|\|[[File:PMC3894017 JFMPC-2-83-g001.png\|250px]] \|\| \|\| \|\|[[File:Red (burning) Skin Syndrome - Feet Collage.jpg\|250px]]
	\|}		\|}

Rossdonaldson1: /* Table of Severe Drug Rashes */

2019-12-17T19:21:35Z

Table of Severe Drug Rashes

← Older revision		Revision as of 19:21, 17 December 2019
Line 32:		Line 32:
	\|-		\|-
	\| '''Mortality''' (%)\|\|10\|\|5-35\|\|5\|\|5-15		\| '''Mortality''' (%)\|\|10\|\|5-35\|\|5\|\|5-15
			\|-
			\| '''Image'''\|\| \|\| \|\| \|\|[[File:Red (burning) Skin Syndrome - Feet Collage.jpg\|250px]]
	\|}		\|}

Rossdonaldson1: /* Table of Severe Drug Reactions */

2019-12-17T19:16:48Z

Table of Severe Drug Reactions

← Older revision		Revision as of 19:16, 17 December 2019
Line 1:		Line 1:
	=== Table of Severe [[Drug Rash~~\|Drug Reactions~~]] ===		=== Table of Severe [[Drug Rash]]es ===
	{\| {{table}}		{\| {{table}}
	\| align="center" style="background:#f0f0f0;"\|'''Charateristic'''		\| align="center" style="background:#f0f0f0;"\|'''Charateristic'''

Rossdonaldson1: /* Table of Severe Drug Reactions */

2019-12-17T19:16:24Z

Table of Severe Drug Reactions

← Older revision		Revision as of 19:16, 17 December 2019
Line 1:		Line 1:
	=== Table of Severe Drug Reactions ===		=== Table of Severe [[Drug Rash\|Drug Reactions]] ===
	{\| {{table}}		{\| {{table}}
	\| align="center" style="background:#f0f0f0;"\|'''Charateristic'''		\| align="center" style="background:#f0f0f0;"\|'''Charateristic'''

Rossdonaldson1: /* Table of Severe Drug Reactions */

2019-12-17T19:15:46Z

Table of Severe Drug Reactions

← Older revision		Revision as of 19:15, 17 December 2019
Line 33:		Line 33:
	\| '''Mortality''' (%)\|\|10\|\|5-35\|\|5\|\|5-15		\| '''Mortality''' (%)\|\|10\|\|5-35\|\|5\|\|5-15
	\|}		\|}
	~~;AGEP Acute generalized exanthematous pustulosis~~
	~~;DRESS drug reaction with eosinophilia and systemic symptoms~~
	~~;SJS Stevens-Johnson syndrome~~
	~~;TEN toxic epidermal necrolysis~~

Rossdonaldson1: /* Table of Severe Drug Reactions */

2019-12-17T19:15:30Z

Table of Severe Drug Reactions

← Older revision		Revision as of 19:15, 17 December 2019
Line 7:		Line 7:
	\| align="center" style="background:#f0f0f0;"\|'''[[Erythroderma]]'''		\| align="center" style="background:#f0f0f0;"\|'''[[Erythroderma]]'''
	\|-		\|-
	\| Onset of eruption\|\|2-6 weeks\|\|1-3 weeks\|\|48 hours\|\|1-3 weeks		\| '''Onset of eruption'''\|\|2-6 weeks\|\|1-3 weeks\|\|48 hours\|\|1-3 weeks
	\|-		\|-
	\| Duration of eruption (weeks)\|\|Several\|\|1-3\|\|<1\|\|Several		\| '''Duration of eruption (weeks)'''\|\|Several\|\|1-3\|\|<1\|\|Several
	\|-		\|-
	\| Fever\|\|+++\|\|+++\|\|+++\|\|+++		\| '''Fever'''\|\|+++\|\|+++\|\|+++\|\|+++
	\|-		\|-
	\| Mucocutaneous features\|\|Facial edema, morbilliform eruption, pustules, exfoliative dermattiis, tense bullae, possible target lesions\|\|Bullae, atypical target lesions, mucocutaneous erosions\|\|Facial edema, pustules, tense bullae, possible target lesions, possibl emucosal involvement\|\|Erythematous plaques and edema affecting >90% of total skin surface with or without diffuse exfoliation		\| '''Mucocutaneous features'''\|\|Facial edema, morbilliform eruption, pustules, exfoliative dermattiis, tense bullae, possible target lesions\|\|Bullae, atypical target lesions, mucocutaneous erosions\|\|Facial edema, pustules, tense bullae, possible target lesions, possibl emucosal involvement\|\|Erythematous plaques and edema affecting >90% of total skin surface with or without diffuse exfoliation
	\|-		\|-
	\| Lymph node enlargement\|\|+++\|\|-\|\|+\|\|+		\| '''Lymph node enlargement'''\|\|+++\|\|-\|\|+\|\|+
	\|-		\|-
	\| Neutrophils\|\|Elevated\|\|Decreased\|\|Very elevated\|\|Elevated		\| '''Neutrophils'''\|\|Elevated\|\|Decreased\|\|Very elevated\|\|Elevated
	\|-		\|-
	\| Eosinophils\|\|Very elevated\|\|No change\|\|Elevated\|\|Elevated		\| '''Eosinophils'''\|\|Very elevated\|\|No change\|\|Elevated\|\|Elevated
	\|-		\|-
	\| Atypical lymphocytes\|\|+\|\|-\|\|-\|\|+		\| '''Atypical lymphocytes'''\|\|+\|\|-\|\|-\|\|+
	\|-		\|-
	\| Hepatitis\|\|+++\|\|++\|\|++\|\|-		\| '''Hepatitis'''\|\|+++\|\|++\|\|++\|\|-
	\|-		\|-
	\| Other organ involvement\|\|Interstitial nephritis, pneumonitis, myocarditis, and thydoiditis\|\|Tubular nephritis and tracheobronical necrosis\|\|Possible\|\|Possible		\| '''Other organ involvement'''\|\|Interstitial nephritis, pneumonitis, myocarditis, and thydoiditis\|\|Tubular nephritis and tracheobronical necrosis\|\|Possible\|\|Possible
	\|-		\|-
	\| Histological pattern of skin\|\|Perivascular lymphocytcic infiltrate\|\|Epidermal necrosis\|\|Subcorneal pustules\|\|Nonspecific, unless reflecting Sezary syndrome or other lymphoma		\| '''Histological pattern of skin'''\|\|Perivascular lymphocytcic infiltrate\|\|Epidermal necrosis\|\|Subcorneal pustules\|\|Nonspecific, unless reflecting Sezary syndrome or other lymphoma
	\|-		\|-
	\| Lymph node histology\|\|Lymphoid hyperplasia\|\|-\|\|-\|\|No, unless reflecting Sezary syndrome or other malignancy		\| '''Lymph node histology'''\|\|Lymphoid hyperplasia\|\|-\|\|-\|\|No, unless reflecting Sezary syndrome or other malignancy
	\|-		\|-
	\| Mortality (%)\|\|10\|\|5-35\|\|5\|\|5-15		\| '''Mortality''' (%)\|\|10\|\|5-35\|\|5\|\|5-15
	\|}		\|}
	;AGEP Acute generalized exanthematous pustulosis		;AGEP Acute generalized exanthematous pustulosis